Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study

Susan O'Brien, Jeffrey A. Jones, Steven E. Coutre, Anthony R. Mato, Peter Hillmen, Constantine Tam, Anders Österborg, Tanya Siddiqi, Michael J. Thirman, Richard R. Furman, Osman Ilhan, Michael J. Keating, Timothy G. Call, Jennifer R. Brown, Michelle Stevens-Brogan, Yunfeng Li, Fong Clow, Danelle F. James, Alvina D. Chu, Michael HallekStephan Stilgenbauer

Research output: Contribution to journal › Article › peer-review

196 Scopus citations

Fingerprint

Dive into the research topics of 'Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study'. Together they form a unique fingerprint.

Medicine & Life Sciences